Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/30437
Title: | Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer | Authors: | BURZYKOWSKI, Tomasz Coart, E. Saad, E.D. Shi, Q. Sommeijer, D.W. Bokemeyer, C. Díaz-Rubio, E. Douillard, Jean-Yves Falcone, A. Fuchs, C. Goldberg, R.M. Hecht, R. Hoff, P.M. Hurwitz, H. Kabbinavar, F.F. Koopman, M. Maughan, T. Punt, C.J.A. Saltz, L. Schmoll, Hans-Joachim Seymour, M.T. Tebbutt, N.C. Tournigand, C. Van Cutsem, E. de Gramont, A. Zalcberg, J.R. BUYSE, Marc |
Issue Date: | 2019 | Publisher: | AMER MEDICAL ASSOC | Source: | JAMA NETWORK OPEN, 2 (9) (Art N° ARTN e1911750) | Abstract: | IMPORTANCE Tumor measurements can be used to estimate time to nadir and depth of nadir as potential surrogates for overall survival (OS).OBJECTIVE To assess time to nadir and depth of nadir as surrogates for OS in metastatic colorectal cancer.DESIGN, SETTING, AND PARTICIPANTS Pooled analysis of 20 randomized clinical trials within the Aide et Recherche en Cancerologie Digestive database, which contains academic and industrysponsored trials, was conducted. Three sets of comparisons were performed: chemotherapy alone, antiangiogenic agents, and anti-epidermal growth factor receptor agents in first-line treatment for patients with metastatic colorectal cancer.MAIN OUTCOMES AND MEASURES Surrogacy of time to nadir and depth of nadir was assessed at the trial level based on joint modeling of relative tumor-size change vs baseline and OS. Treatment effects on time to nadir and on depth of nadir were defined in terms of between-arm differences in time to nadir and in depth of nadir, and both were assessed in linear regressions for their correlation with treatment effects (hazard ratios) on OS within each set. The strengths of association were quantified using sample-size-weighted coefficients of determination (R-2), with values closer to 1.00 indicating stronger association. At the patient level, the correlationwas assessed between modeled relative tumor-size change and OS.RESULTS For 14 chemotherapy comparisons in 4289 patients, the R2 value was 0.63 (95% CI, 0.300.96) for the association between treatment effects on time to nadir and OS and 0.08 (95% CI, 0-0.37) for depth of nadir and OS. For 11 antiangiogenic agent comparisons (4854 patients), corresponding values of R-2 were 0.25 (95% CI, 0-0.72) and 0.06 (95% CI, 0-0.35). For 8 antiepidermal growth factor receptor comparisons (2684 patients), corresponding values of R-2 were 0.24 (95% CI, 0-0.83) and 0.21 (95% CI, 0-0.78).CONCLUSIONS AND RELEVANCE In contrast with early reports favoring depth of response as a surrogate, these results suggest that neither time to nadir nor depth of nadir is an acceptable surrogate for OS in the first-line treatment of metastatic colorectal cancer. | Document URI: | http://hdl.handle.net/1942/30437 | ISSN: | 2574-3805 | e-ISSN: | 2574-3805 | DOI: | 10.1001/jamanetworkopen.2019.11750 | ISI #: | WOS:000488882800054 | Rights: | Open Access. This is an open access article distributed under the terms of the CC-BY License | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2021 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
burzykowski_2019_oi_190453.pdf | Published version | 1.07 MB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
7
checked on Oct 8, 2024
Page view(s)
38
checked on Sep 7, 2022
Download(s)
16
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.